MedPath

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

Phase 2
Recruiting
Conditions
Cutaneous Melanoma
Mucosal Melanoma
Interventions
Drug: Nemvaleukin Alfa Subcutaneous
Drug: Nemvaleukin Alfa Intravenous
Drug: Nemvaleukin Alfa Intravenous Less Frequent Dosing
Drug: Pembrolizumab
Registration Number
NCT04830124
Lead Sponsor
Mural Oncology, Inc
Brief Summary

This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
180
Inclusion Criteria
  • The patient must have the following tumor types:

Cohort 1: Patient has unresectable and/or metastatic cutaneous melanoma. No more than 5 patients with acral melanoma may enroll in this cohort.

Cohort 2: Patient has unresectable and/or metastatic mucosal melanoma.

Cohort 3: Patient has unresectable and/or metastatic cutaneous melanoma. Patients with acral melanoma may not enroll in this cohort.

Cohort 4: Patient has unresectable and/or metastatic cutaneous melanoma. No patients with mucosal or acral melanoma may enroll in this cohort.

  • The patient must have received previous treatment as follows: Cohorts 1 and 2: Patient has received anti-PD-[L]1 therapy with or without anti-CTLA-4 therapy, and less than or equal to one other prior regimen of systemic anti-neoplastic therapy (eg, targeted therapy, chemotherapy). Previous adjuvant and/or neoadjuvant therapy counts as one prior regimen. Patients have experienced objective response (partial response [PR] or CR; by RECIST 1.1 or iRECIST) or stable disease (SD; by RECIST 1.1 or iRECIST) as best overall response (BOR) to anti-PD-[L]1 therapy. Patients with confirmed progressive disease (by RECIST 1.1 or iRECIST) as best response may be included, if they received anti-PD-[L]1 therapy for a minimum of 12 weeks (eg, from first dose to last dose). Patients with BRAF mutations may or may not have received prior targeted therapy.

Cohort 3: Patients who have received anti-PD-[L]1 therapy with or without anti-CTLA-4 therapy or anti-lymphocyte-activation gene 3 (LAG-3) therapy, and ≤1 other prior regimen of systemic anti-neoplastic therapy (eg, targeted therapy, chemotherapy). Previous adjuvant and/or neoadjuvant therapy counts as 1 prior regimen. Patients must have experienced objective response (PR or CR by RECIST 1.1 or iRECIST) or stable disease (by RECIST 1.1 or iRECIST) as BOR to anti PD-[L]1 therapy. Patients with confirmed progressive disease (by RECIST 1.1 or iRECIST) as best response may be included, if they received anti-PD-[L]1 therapy for ≥12 weeks (from first dose to last dose). Patients with BRAF mutations may or may not have received prior targeted therapy.

Cohort 4: Patients must not have received prior systemic anticancer therapy for unresectable or metastatic melanoma. Prior adjuvant and/or neoadjuvant PD-[L]1 treatments are allowed if there is at least 6 months between the last dose and date of recurrence.

Cohorts 1, 2, and 3 - Patients who have received prior treatment with talimogene laherparepvec (TVEC) are allowed to enroll provided that last exposure to TVEC was ≥28 days prior to first exposure to nemvaleukin and that all injection-site reactions to TVEC have resolved. TVEC shall not be considered a prior regimen of systemic anti-neoplastic therapy, nor shall it be considered a systemic immunomodulatory agent.

  • Patients must have disease that is measurable based on RECIST 1.1., that has not recently been irradiated or used to collect a biopsy.
  • Cohorts 1 and 2 (required), Cohort 3 (optional), Cohort 4 (may be required, otherwise optional). Patient is willing to undergo a pretreatment tumor biopsy or provide qualifying archival tumor tissue.

Cohort 4 - Patients are required to have known tumor PD-[L]1 status determined by local testing using an approved assay. PD-[L]1 testing performed prior to enrolling on the study is acceptable if there was no intervening systemic anti-cancer therapy, and archival tissue may be used for testing provided the biopsy is ≤3 months old.

  • Patient has an Eastern Cooperative Oncology Group (ECOG) status of 0 or 1 and an estimated life expectancy of ≥3 months.
  • Additional criteria may apply.
Read More
Exclusion Criteria
  • Patient has uveal melanoma (all cohorts) or acral melanoma (Cohort 2, Cohort 3 and Cohort 4).
  • Patient has received prior interleukin (IL)-2-based or IL-15-based cytokine therapy; patient has had exposure, including intralesional, to IL-12 or analogs thereof.
  • Patient requires systemic corticosteroids (>10 mg of prednisone daily, or equivalent) however, replacement doses, topical, ophthalmologic, and inhalational steroids are permitted.
  • Patient has undergone prior solid organ and/or non-autologous hematopoietic stem cell or bone marrow transplant.
  • Patient is currently pregnant, breastfeeding, or is planning to become pregnant or to begin breastfeeding during the study period or within 30 days (Cohorts 1,2, and 3) or 120 days (Cohort 4) after last study drug administration.
  • Patients with active or symptomatic central nervous system metastases unless the metastases have been treated by surgery and/or radiation therapy and/or gamma knife, the subject has been tapered to a dose of 10 mg of prednisone (or equivalent) or less of corticosteroids for at least 2 weeks before the first dose, and the subject is neurologically stable. Patients with leptomeningeal disease are excluded.
  • Patient has known or suspected hypersensitivity to any components of nemvaleukin (all cohorts) or to pembrolizumab (cohort 4 only).
  • Patients with an uncontrollable bleeding disorder.
  • Patient has QT interval corrected by the Fridericia Correction Formula values of >470 msec (in females) or >450 msec (in males); patient who is known to have congenital prolonged QT syndromes; or patient who is on medications known to cause prolonged QT interval on ECG.
  • Patient has developed Grade ≥3 immune-related AEs (irAEs) while on prior immunotherapy, (eg, pneumonitis and nephritis) and has not recovered to ≤Grade 1 and/or are on systemic steroids within 14 days of first dose of study drug.
  • Patients who have previously discontinued immunotherapy due to immune-related adverse event (irAEs) will be excluded.
  • Cohort 4 only: Patient has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis.
  • Additional criteria may apply.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Advanced Cutaneous Melanoma Subcutaneous Dosing (Cohort 1)Nemvaleukin Alfa SubcutaneousPatients with unresectable and/or metastatic cutaneous melanoma
Advanced mucosal melanoma with IV Dosing (Cohort 2)Nemvaleukin Alfa IntravenousPatients with unresectable and/or metastatic mucosal melanoma
Advanced Cutaneous Melanoma with Less Frequent IV Dosing (Cohort 3)Nemvaleukin Alfa Intravenous Less Frequent DosingPatients with unresectable and/or metastatic cutaneous melanoma
Advanced Cutaneous Melanoma with Less Frequent IV Nemvaleukin Dosing + Pembrolizumab (Cohort 4)Nemvaleukin Alfa Intravenous Less Frequent DosingPatients with unresectable and/or metastatic cutaneous melanoma. Patients must not have received prior systemic anticancer therapy for unresectable or metastatic melanoma. Prior adjuvant and/or neoadjuvant PD-\[L\]1 treatments are allowed if there is at least 6 months between the last dose and date of recurrence.
Advanced Cutaneous Melanoma with Less Frequent IV Nemvaleukin Dosing + Pembrolizumab (Cohort 4)PembrolizumabPatients with unresectable and/or metastatic cutaneous melanoma. Patients must not have received prior systemic anticancer therapy for unresectable or metastatic melanoma. Prior adjuvant and/or neoadjuvant PD-\[L\]1 treatments are allowed if there is at least 6 months between the last dose and date of recurrence.
Primary Outcome Measures
NameTimeMethod
Centrally-assessed overall response rate (ORR) (Cohort 1 and 2)Assessed up to 2 years from the first dose

* ORR is defined as the number of patients exhibiting a complete response (CR) or partial response (PR) divided by the number of patients who received the study drug

* Response will be based on RECIST v1.1 criteria

Investigator-assessed overall response rate (ORR) (Cohort 3 and 4)Assessed up to 2 years from the first dose

ORR is defined as the number of patients exhibiting a complete response (CR) or partial response (PR) divided by the number of patients who received the study drug

Secondary Outcome Measures
NameTimeMethod
Centrally-assessed duration of response (DOR) (Cohort 1 and 2)Assessed up to 2 years from the first dose

-DOR is defined as the time from the first documentation of complete or partial response to the first documentation of either objective tumor progression or death

Investigator-assessed duration of response (DOR) (Cohort 3 and 4)Assessed up to 2 years from the first dose

-DOR is defined as the time from the first documentation of complete or partial response to the first documentation of either objective tumor progression or death

Centrally-assessed progression free survival (PFS) (Cohort 1 and 2)Assessed up to 2 years from the first dose

-PFS is defined as the time from each respective patient's first dose of nemvaleukin to either the first documentation of objective tumor progression or death

Investigator-assessed progression free survival (PFS) (Cohort 3 and 4)Assessed up to 2 years from the first dose

-PFS is defined as the time from each respective patient's first dose of nemvaleukin to either the first documentation of objective tumor progression or death

Centrally-assessed disease control rate (DCR) (Cohort 1 and 2)Assessed up to 2 years from the first dose

-DCR is defined as the proportion of patients with objective evidence of complete response, partial response, or stable disease on 2 consecutive protocol-required disease assessments

Investigator-assessed disease control rate (DCR) (Cohort 3 and 4)Assessed up to 2 years from the first dose

-DCR is defined as the proportion of patients with objective evidence of complete response, partial response, or stable disease on 2 consecutive protocol-required disease assessments

Centrally-assessed time to response (TTR) (Cohort 1 and 2)Assessed up to 2 years from the first dose

-TTR is defined as the time from patient's first dose of nemvaleukin to the first documentation of complete response or partial response

Investigator-assessed time to response (TTR) (Cohort 3 and 4)Assessed up to 2 years from the first dose

-TTR is defined as the time from patient's first dose of nemvaleukin to the first documentation of complete response or partial response

Incidence of treatment-emergent adverse events (All cohorts)Assessed up to 2 years from the first dose
Investigator-assessed overall response rate (ORR) (Cohort 1 and 2)Assessed up to 2 years from the first dose

ORR is defined as the number of patients exhibiting a complete response (CR) or partial response (PR) divided by the number of patients who received the study drug

Investigator-assessed immune overall response rate (iORR) (All cohorts)Assessed up to 2 years from the first dose

-iORR is defined as the number of patients exhibiting a complete response (CR) or partial response (PR) divided by the number of patients who received the study drug.

Investigator-assessed immune duration of response (iDOR) (All cohorts)Assessed up to 2 years from the first dose

-iDOR is defined as the time from the first documentation of complete or partial response to the first documentation of either objective tumor progression or death

Investigator-assessed immune progression free survival (iPFS) (All cohorts)Assessed up to 2 years from the first dose

-iPFS is defined as the time from each respective patient's first dose of nemvaleukin to either the first documentation of objective tumor progression or death

Investigator-assessed immune disease control rate (iDCR) (All cohorts)Assessed up to 2 years from the first dose

-iDCR is defined as the proportion of patients with objective evidence of complete response, partial response, or stable disease on 2 consecutive protocol-required disease assessments

Investigator-assessed immune time to response (iTTR) (All cohorts)Assessed up to 2 years from the first dose

-iTTR is defined as the time from patient's first dose of nemvaleukin to the first documentation of complete or partial response

Trial Locations

Locations (43)

Kaohsiung Chang Gung Memorial Hospital

🇨🇳

Kaohsiung, Taiwan

UT Southwestern Medical Center of Dallas

🇺🇸

Dallas, Texas, United States

Hospital Clinic Barcelona

🇪🇸

Barcelona, Spain

Princess Margaret Cancer Centre

🇨🇦

Toronto, Ontario, Canada

John Flynn Private Hospital

🇦🇺

Tugun, Queensland, Australia

McGill University Health Center (MUHC)

🇨🇦

Montréal, Quebec, Canada

Fondazione IRCC Istituto Nazionale dei Tumori

🇮🇹

Milano, Italy

The Queen Elizabeth Hospital

🇦🇺

Woodville, Australia

Memorial Sloan Kettering Cancer Center

🇺🇸

New York, New York, United States

Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari

🇮🇹

Bari, Italy

UC San Diego Moores Cancer Center

🇺🇸

La Jolla, California, United States

Ospedale S. Maria della Misericordia

🇮🇹

Perugia, Italy

Samsung Medical Center

🇰🇷

Gangam-gu, Seoul, Korea, Republic of

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center

🇺🇸

Boston, Massachusetts, United States

Hospital Universitario Quiron Pozuelo

🇪🇸

Madrid, Spain

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

The Angeles Clinic and Research Institute

🇺🇸

Los Angeles, California, United States

Regions Hospital

🇺🇸

Saint Paul, Minnesota, United States

Columbia University Medical Center

🇺🇸

New York, New York, United States

NYU Laura and Isaac Perimutter Cancer Center

🇺🇸

New York, New York, United States

Calvary Mater Newcastle

🇦🇺

Waratah, New South Wales, Australia

Centre Hospitalier de l'Universite de Montreal (CHUM)

🇨🇦

Montreal, Quebec, Canada

IRCCS Istituti Fisioterapici Ospitalieri

🇮🇹

Roma, Italy

Veneto Oncology Institute

🇮🇹

Padova, Italy

Severance Hospital Yonsei University Health System

🇰🇷

Seoul, Seodaemun-Gu, Korea, Republic of

Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte

🇮🇹

Siena, Italy

Seoul National University Hospital

🇰🇷

Jongno-gu, Seoul, Korea, Republic of

The Catholic Univ. of Korea, Seoul St. Marys Hospital

🇰🇷

Seoul, Seocho-gu, Korea, Republic of

Kyungpook National University Chilgok Hospital

🇰🇷

Daegu, Korea, Republic of

Hospital Universitario Vall d'Hebron

🇪🇸

Barcelona, Spain

Hospital General Universitario

🇪🇸

Madrid, Spain

Taipei Veterans General Hospital, VGHTPE

🇨🇳

Taipei, Taiwan

Hospital Regional de Málaga

🇪🇸

Málaga, Spain

Chang Gung Memorial Hospital LinKou

🇨🇳

Taoyuan, Taiwan

Royal Marsden Hospital

🇬🇧

London, United Kingdom

The Christie Hospital

🇬🇧

Manchester, United Kingdom

The Churchill Hospital

🇬🇧

Oxford, United Kingdom

Chungnam National University Hospital

🇰🇷

Daejeon, Korea, Republic of

Orlando Health, Inc

🇺🇸

Orlando, Florida, United States

Norton Cancer Center

🇺🇸

Louisville, Kentucky, United States

Asan Medical Center

🇰🇷

Songpa-Gu, Seoul, Korea, Republic of

Hospital Universitario Miguel Servet

🇪🇸

Zaragoza, Spain

© Copyright 2025. All Rights Reserved by MedPath